Candel Therapeutics Appoints New Board Member

Candel Therapeutics ( (CADL) ) has shared an announcement.

On June 4, 2025, Candel Therapeutics announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors, expanding the board from nine to ten members. Dr. Radhakrishnan, with extensive experience in product development and commercialization, is expected to play a crucial role as Candel advances its late-stage oncology programs, including the anticipated Biologics License Application submission for CAN-2409 in prostate cancer by Q4 2026.

The most recent analyst rating on (CADL) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.

Spark’s Take on CADL Stock

According to Spark, TipRanks’ AI Analyst, CADL is a Underperform.

Candel Therapeutics is currently facing substantial financial challenges with no revenue and ongoing cash burn, which heavily weighs down its stock score. Despite positive clinical trial results offering future potential, the current technical and valuation metrics remain unfavorable, reflecting the speculative nature of the stock.

To see Spark’s full report on CADL stock, click here.

More about Candel Therapeutics

Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The company has established two clinical-stage multimodal biological immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, with CAN-2409 and CAN-3110 as their lead product candidates.

Average Trading Volume: 993,999

Technical Sentiment Signal: Hold

Current Market Cap: $280.6M

See more data about CADL stock on TipRanks’ Stock Analysis page.